The analysis of the market of metformin-based drugs




antidiabetic drugs, type II diabetes mellitus, economic accessibility, pharmaceutical market


Aim. To analyze the market of antidiabetic drugs based on metformin; to substantiate the feasibility of introducing a new combined drug for the treatment of type II diabetes mellitus.
Materials and methods. The theoretical basis of the research is the scientific works of domestic and foreign scientists. The empirical basis of the study is the State Register of Drugs, State Formulary of Drugs, price lists, and statistical data for 2012-2017. The analysis of price indicators was performed using statistical methods; the cost of a new drug was calculated.
Results. The analysis of the market of oral antidiabetic drugs has been performed by dosage forms, the composition of active substances, the forms of release and countries of origin. Currently, in Ukraine 102 names of metformin-based medicines in the form of tablets – 500 mg, 850 mg and 1000 mg – have been registered, among them 74.5 % of drugs are of foreign origin. A combined drug with a hypoglycemic action (in capsules) containing metformin and benfotiamine has been developed and it has no analogs in Ukraine. The analysis of the price indices of antidiabetic medicinal products indicates their economic accessibility to the population, which has increased significantly due to the introduction of the state regulation (up to 70 %). The forecasted price of the new combined drug has been calculated, the wholesale-selling price calculated for DDD is 2.92 UAH. Thus, the conclusion can be made about the economic feasibility for manufacturing the new combined antidiabetic drug.              Conclusions. The use of a combination of metformin and benfotiamine for the treatment of type ІІ diabetes will reduce the negative consequences of complications of the disease (diabetic polyneuropathy, nephropathy, retinopathy) and avoid significant economic losses.


United Nations. General Assembly. (2006). Resolution adopted by the General Assembly on 20 December 2006 without reference to a Main 61/225. Available at: https://documents–dds– doc/UNDOC/GEN/N06/507/87/PDF/N0650787.pdf?OpenElement.

International Diabetes Federation. (2017). IDF Diabetes Atlas. Available at:

Germanyuk, Т. А., Іvko, Т. І. (2014). Rational choice of monotherapy for the treatment of type 2 diabetes mellitus based on the pharmacoeconomical analysis. Sci.Rise, 4 (5), 69–72.

Brink, S. J., Lee, W., Pillay, K., Kleinebreil, L. (2010). Diabetes in children and adolescents. Diagnosing diabetes in children treating diabetes talking to patients about diabetes organisation of diabetes care. Novo Nordisk: ISPAD, 101.

World Health Organization. (2016). Global report on Diabetes. Geneva: WHO. Available at: http://–report

Hermaniuk, T., Ivko, T. (2012). Investigation of Pharmaceutical Market of Peroral Hypoglycemic Drugs in Vinnitsa Region and Choice of Minimally Costly Treatment Regimen for 2 Type Diabetes Mellitus. Liky Ukrainy, 8 (164), 58–63.

Hermaniuk, T., Ivko, T. (2012). Marketing research of pharmaceutical market : theory and practice. Visnyk Vinnytskoho natsionalnoho medychnoho universytetu, 2 (19), 495–497.

Proekt postanovy Kabinetu Ministriv Ukrainy “Pro zatverdzhennia Poriadku vidshkoduvannia vartosti preparativ insulinu”. Available at:

Ukrainian database of medical and statistical information. Available at: normdoc/vooz.html. (In Ukrainian).

10. Resolution of the Cabinet of Ministers of Ukraine 17.03.2017 No. 152 “About the availability of medicines”. Available at:

Order of the Ministry of Health of Ukraine dated 21.12.2012 No.1118 “On Approving and Implementation of Medical–Technological Documents on the Standardization of Medical Aids in Type 2 Diabetes”. Available at:–mtd/item/33–tsukrovyi–diabet–1–


Order of the Ministry of Health of Ukraine dated 21.12.2012 No.1118 “A unified clinical protocol for primary and secondary (specialized) medical care”. Available at: dod1118_2_2012.pdf

WHO. (2016). Anatomical Therapeutic Chemical (АТС) classification system. Available at: http://

Nemchenko, A. S., Tsubanova, N. A., Bezchasniuk, O. M., Hubar, S. M., Yevsieieva, L. V., Toraiev, K. N. (2018). Antydiabetychnyi zasib. Kyiv, 9.

Chacra, A. (2012). Evolving metformin treatment strategies in type–2 diabetes: from immediate–release metformin monotherapy to extended–release combination therapy. Endokrynolohiia, 17 (4), 82–90.

The list of medicines under the National List of Essential Medicines and Medical Devices. Available at:

Draft Resolution of the Cabinet of Ministers of Ukraine “On amending paragraph 1 of the Procedure for reimbursement of the cost of insulin preparations”. Available at: portal/Pro_20170411_0.html

Order of the Ministry of Health of Ukraine dated 26.07.2017 No.856 “On approval of the Register of Medicines, the value of which is subject to reimbursement as of July 26, 2017”. Available at: http://

Register of wholesale and retail prices for medicines. Available at: register_prices_drugs/

State Formular of medicines. Issue 9. Available at:– poshukova–sistema–elektronnij–formulyar

Toraiev, K. N., Nemchenko, A. S., Tsubanova, N. A., Bezchasniuk, O. M., Hubar, S. M., Yevsieieva, L. V. (2017). Pharmaceutical composition with antidiabetic effect for the treatment of type II diabetes mellitus. Patent of Ukraine UA 116290 U, MPK (2017.01) A61K9/20 A61K31/64 A61P35/00 № u201612858; declared 19.12.2016; published 10.05.2017, № 9.





Social marketing and pharmacoeconomic research